FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET

Company Participants

Joanne Greller - LifeSci Advisors
Thane Wettig - Chief Executive Officer
David DeLucia - Chief Financial Officer

Conference Call Participants

Andy Hsieh - William Blair
Matthew Keller - H.C. Wainwright

Operator

Good day and thank you for standing by. Welcome to FibroGen First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today Joanne Greller. Please go ahead.

Joanne Greller

Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss FibroGen's first quarter 2025 financial and business results. I'm Joanne Greller from LifeSci Advisors.

Joining me on today's call are Thane Wettig, our Chief Executive Officer; and David DeLucia, our Chief Financial Officer. Following the prepared remarks, we will open the call to your questions.

I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to our collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct and results of clinical trials, our regulatory strategies and potential regulatory results, our research and development activities, commercial results and results of operations risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statements. A more complete description of these and other material risks can be found in FibroGen's filings with the SEC, including our most recent Form 10-K and Form 10-Q.

FibroGen does